Functional Analysis of PS1 Interacting Protein PSIP1
About the Research Project
Program
Award Type
Standard
Award Amount
$98,445
Active Dates
April 01, 2005 - March 31, 2007
Grant ID
A2005319
Summary
Over the past decade, molecular geneticists have identified genes that are mutated in families with early-onset forms of AD. These genes encode presenilin 1 (PS1), presenilin 2 (PS2), and APP. G-secretase is a large macromolecular complex that consists of presenilin and several additional proteins. The focus of Dr. Zhang’s project is to examine the cell biology of another protein, termed PSIP1, an evolutionary conserved molecule with no known function. Dr. Zhang has confirmed the association of PSIP1 and PS1 in stable cell lines, and has developed highly specific anti-PSIP1 antibodies to examine the subcellular distribution and trafficking of this protein. Understanding of the molecular mechanism(s) by which PSIP1 modulates g-secretase processing may offer new insights into potential targets for therapeutic intervention in AD.
Grants
Related Grants
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD